#United States #New York #Class Action #Gross Law Firm #Unicycive Therapeutics

Unicycive Therapeutics Faces a Class Action Lawsuit

The Gross Law Firm has recently announced a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This notice is aimed at shareholders who acquired shares of Unicycive during the specified class period from March 29, 2024, to June 27, 2025. It is crucial for affected investors to be aware of their rights and the potential for recovery through this lawsuit.

Background of the Lawsuit

The complaint filed against Unicycive alleges several significant issues regarding the company's public communications during the class period. Specifically, the lawsuit claims that Unicycive provided materially false and misleading statements, which included:

1. Overstated Manufacturing Compliance: The allegations mention that Unicycive exaggerated its readiness and capability to meet the FDA’s manufacturing compliance requirements.
2. Regulatory Prospects of New Drug Application: It is claimed that the company's aspirations regarding the regulatory prospects of its oxylanthanum carbonate new drug application were similarly overstated.
3. Material Misrepresentation During Class Period: As a result of these misleading statements, the lawsuit argues that the public statements made by the company were not only inaccurate but also damaging to shareholders.

What This Means for Shareholders

Shareholders who purchased Unicycive stock during the class period are encouraged to report their information to the Gross Law Firm for potential lead plaintiff appointment. It's important to note that appointments are not mandatory to partake in any recovery resulting from the lawsuit.

Upcoming Deadline

Investors should take action promptly, as the deadline to register for this class action is October 14, 2025. Those interested in participating must act swiftly to ensure their rights are protected and that they are considered for recovery should the lawsuit lead to a settlement or judgment in favor of the shareholders.

Next Steps for Affected Investors

Once a shareholder registers, they will be enrolled in a portfolio monitoring system that will provide status updates related to the case’s progression. There is no financial obligation involved in registering for the lawsuit.

The Role of the Gross Law Firm

The Gross Law Firm is a reputable name in the realm of class action lawsuits, and its mission centers on safeguarding the interests of investors who have suffered losses due to misleading corporate practices. The firm emphasizes the importance of corporate responsibility and aims to hold companies accountable for their actions that affect investors.

For shareholders affected by this situation, the Gross Law Firm stands ready to provide assistance and ensure that their rights are upheld in light of the alleged misconduct by Unicycive Therapeutics.

How to Contact

For further inquiries or to join the class action, shareholders are advised to visit Gross Law Firm's website. The firm encourages any individuals who have invested in Unicycive during the specified class period to take action and secure their potential claims.

Time is of the essence, and prompt registration could make a significant difference in the recovery process for shareholders.

Final Thoughts

This notice serves as a critical reminder that investors should always remain vigilant regarding their investments. Misleading statements from companies can have dire consequences, and it is vital to understand the implications of such actions. The Gross Law Firm aims to ensure that stakeholders are granted proper recourse through this class action lawsuit as they navigate these challenges together.